INC Research and Debiopharm Group ™ Announce Strategic Partnership
News Jul 27, 2011
INC Research, LLC, a therapeutically focused contract research organisation (CRO) with a trusted process for delivering reliable results, and Debiopharm Group™, a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, have announced a strategic partnership.
Under the terms of the agreement, Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline. Both parties have furthermore agreed on a framework partnership pertaining to future clinical studies to be conducted by INC Research for Debiopharm.
“Debiopharm’s reputation and success in establishing partnerships is aligned very closely with our vision of creating strategic relationships that improve the speed, efficiency, and quality of drug development,” said Kelvin Logan, Ph.D., president INC Research Europe and Asia Pacific, who added “we are pleased to offer our therapeutic expertise along with our experience in conducting trials globally to support Debiopharm’s drug development efforts in bringing innovative medicines to market more quickly and efficiently.”
“It is through our successful partnerships that we have been able to build and maintain a truly leading global biopharmaceutical development group, while supporting and conducting several clinical development programmes on a continuous basis” said Dr Rolland-Yves Mauvernay, President and Founder of Debiopharm.
Dr Mauvernay continued, “This partnership with INC Research will significantly help us in our endeavours to conduct our clinical development programmes efficiently, which in turn will enable us to continue to fuel our pipeline with important new medicines.”
INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer.
The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process® provides the foundation for successful strategic alliances.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE